



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,729	04/30/2001	George Jackowski	2132.031	3806

21917 7590 05/04/2004

MCHALE & SLAVIN, P.A.  
2855 PGA BLVD  
PALM BEACH GARDENS, FL 33410

EXAMINER
----------

NGUYEN, BAO THUY L

ART UNIT	PAPER NUMBER
----------	--------------

1641

DATE MAILED: 05/04/2004

19

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/845,729

**Applicant(s)**

JACKOWSKI ET AL.

**Examiner**

Bao-Thuy L. Nguyen

**Art Unit**

1641

-- Th MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 6/13/03 & 10/3/03.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1 and 36-43 is/are pending in the application.
- 4a) Of the above claim(s) 1 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 26-43 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: \_\_\_\_\_

Art Unit: 1641

### DETAILED ACTION

1. The examiner of record for this application has been changed from Lisa Cook to Bao-Thuy Nguyen. All communications should be directed to Thuy Nguyen whose phone number and office hours may be found at the end of this action.
2. Applicant's amendment dated 6/13/2003 as well as the supplemental response dated 10/3/2003 has been received.
3. Claims 2-35 have been cancelled. Claims 36-43 have been added. Claims 1 and 36-43 are pending.
4. Claim 1 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 13.
5. This application contains a claim drawn to an invention nonelected with traverse in Paper No. 13. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

### *Specification*

6. The amendment filed June 13, 2003 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the alteration of SEQ ID NO. 1 is improper. Therefore, the changes to Figures 1 and 2 are improper.

Applicant is required to cancel the new matter in the reply to this Office Action.

*Claim Rejections - 35 USC § 112, second paragraph*

7. Claims 36-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 36-40 are vague and indefinite with respect to the recitation in step c. It is unclear what criteria are used in comparing the mass spectrum profile of the detected sample to the mass spectrum profile of a peptide having amino acid residues 2-14 of SEQ ID NO. 1 (herein after SEQ ID No. 1). Does this mean a 100% match? Is it the same to say that detection of SEQ ID NO. 1 in the patient sample is diagnostic for myocardial infarction? If so, it is suggested that applicant amends the claims such as to clearly and concisely claim the invention.

The claims are also confusing because it is unclear what characteristics are used as the basis of comparison. These “characteristics” have not been clearly defined.

Claims 36-40 are vague and indefinite because it is unclear how one may positively identify a patient as suffering from either renal failure or myocardial infarction or both, by the identification of a mass spectrum profiles of peptides in a sample that display the characteristic profile of the mass spectrum profile of SEQ ID NO. 1.

*Claim Rejections - 35 USC § 112, first paragraph*

8. Claims 36-43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Art Unit: 1641

SEQ ID No. 1 has been amended such that it does not find support in the specification as originally filed. A preliminary amendment filed on April 23, 2002 deleted the amino acid listing (SESDFLAEGGGVR) in the specification and replaced it with "SEQ ID NO. 1". This amendment further identified SEQ ID NO. 1 as a peptide having a molecular weight of about 1350 daltons. A CRF for SEQ ID No. 1 dated February 6, 2003 was submitted identifying SEQ ID NO. 1 as a biopolymer marker having 13 amino acids (SESDFLAEGGGVR). Subsequently, a new sequence listing was submitted (dated June 17, 2003) modifying SEQ ID NO. 1 by adding 2 more amino acid residues to the beginning and end of the peptide. Therefore, SEQ ID NO. 1 is currently a peptide having 15 amino acids; this is an improper addition of material to the specification. The invention, as amended, is different from what is defined in the claim(s) and the originally specification because nothing in the specification leads one to predict that the peptide comprises 15 amino acids with the first and last being Asp and Gly respectively.

Applicant is required to cancel the new matter in response to this final action.

9. Newly added claims 41-43 recite a test kit comprising an antibody that binds to a peptide consisting of amino acid residues 2-14 of SEQ ID NO. 1 in the sample of a patient and a biopolymer marker peptide consisting of amino acids residues 2-14 of SEQ ID No. 1. Such a test kit is not supported by the specification as originally filed. The specification does not contain any discussion of a test kit comprising the reagents state above. The specification at page 18, lines 5-7 briefly recites a diagnostic kit for determining the presence of a disease specific marker; however, there is no recitation of what is in the kit. Applicant is required to cancel the new matter. In the event that Applicant believes support for the kit can be found in the specification

Art Unit: 1641

it is respectfully requested that Applicant points to the page and line number where such support may be found.

**10.** Claims 36-40 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Newly added claims 36-40 recite a method for diagnosing myocardial infarction or renal failures by detecting a biopolymer marker from a patient sample and comparing the detected biopolymer marker to the biopolymer marker having SEQ ID NO. 1 (residues 2-14). Recognition of a mass spectrum profile in the detected sample displaying the characteristic profile of the mass spectrum profile of SEQ ID No. 1 (2-14) is diagnostic for myocardial infarction or renal failure. Such a method is not supported by the specification as originally filed.

The specification at pages 26-31 discloses how a biopolymer marker identified as SEQ ID NO. 1 was identified from patient serum samples, however, nowhere in the specification is there is teaching of detecting any other biopolymer marker, comparing the detected marker to SEQ ID NO. 1, and determining a disease state from the detected marker. Furthermore, it is unclear what criteria are used in comparing the mass spectrum profile of the detected sample to the mass spectrum profile of SEQ ID NO. 1. The claim recites that recognition of a mass spectrum profile in the sample displaying the characteristic profile of mass spectrum profile for the peptide consisting of SEQ ID NO. 1 is diagnostic for MI or renal failure; however, there is no

Art Unit: 1641

clear teaching of this in the specification or anywhere else how this is accomplished. Applicant is required to cancel the new matter.

**11.** Claims 36-40 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Enablement requires that the specification teach those in the art to make and use the invention without undue experimentation. Factors to be considered in determining whether a disclosure would require undue experimentation include (1) the nature of the invention, (2) the state of the prior art, (3) the predictability or lack thereof in the art, (4) the amount of direction or guidance present, (5) the presence or absence of working examples, (6) the quantity of experimentation necessary, (7) the relative skill of those in the art, and (8) the breadth of the claims.

Claims 36-40 are directed to a method for diagnosing myocardial infarction or renal failure by detecting at least one biopolymer marker from a patient sample and comparing the detected biopolymer to SEQ ID NO. 1. Recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for SEQ ID NO. 1 is diagnostic for myocardial infarction or renal failure. Such a method has not been describe in the specification in such a way as to enable one skill in the art to make and use the invention as claimed.

The specification states that a biopolymer marker having SEQ ID NO. 1 was found in serum samples of patients suffering from a variety of disease states (specification, page 26, lines 20-22) including MI and renal failure, (specification, page 27, line 17 through page 28, line 2.)

Art Unit: 1641

However, the specification does not have any data supporting this assertion. Data presented in Figure 1 and in the declaration dated October 3, 2003 is not convincing, nor does it clearly demonstrate that SEQ ID NO. 1 is indicative of MI or renal failure. The specification at page 26, line 20 teaches that serum samples from patients suffering from a variety of diseases were analyzed using protein chips and the profiles were analyzed to discern notable sequences that were deemed in some way evidentiary of at least one disease state. The specification goes on to say that the samples were concentrated by centrifugation and the filtrate was discarded and the retained solution, containing two peptides of interest, was analyzed by tandem mass spectrometry. As a result of these procedures the disease specific marker consisting of SEQ ID NO. 1 was found. The specification asserts that from data set forth in Figure 1, this marker is indicative of MI or renal failure.

It is unclear how SEQ ID NO. 1 was identified as a "notable sequence" or how it was deemed "evidentiary" of a disease state. There is nothing specific in the procedure that would enable one to choose SEQ ID NO. 1 as a notable sequence among all other possible proteins or peptides present in the sample. There is no nexus between the procedure for screening samples from patients suspected of having a variety of different diseases, identifying SEQ ID NO. 1 as a disease marker, and determining that SEQ ID NO. 1 is diagnostic for MI or renal failure. Furthermore, there is no clear teaching that having detected SEQ ID NO. 1 in a sample, how one may definitely diagnose a patient as either suffering from MI or renal failure or both.

According to Strongin (1993, "Sensitivity, Specificity, and Predictive Value of Diagnostic Tests: Definitions and Clinical Applications", in *Laboratory Diagnosis of Viral Infections*, Lennette, e., ed., Marcel Dekker, Inc., New York, pp. 211-219) a number of characteristics need to be considered in the development of any suitable diagnostic assay. These characteristics



Art Unit: 1641

include the following: (1) the sensitivity of the assay; (2) the true-positive test rate; (3) the false-negative test rate; (4) the specificity, or percentage of patients without the disease who will display a negative results; (5) the true-negative test rate; (6) the false-positive test rate; (7) the predictive value, or the probability that the test result is correctly indicating the presence or absence of the disease; (8) the prevalence, or number of patients in any given population that have the disease in question; (9) the efficiency or percentage of all results that are true; (10) the accuracy of the recited diagnostic assay. Additional considerations must also be examined to enable the clinician to practice the invention including assessment of the following: (1) when is the maximum sensitivity desired?; (2) when is the maximum specificity desired?; (3) when is the maximum efficiency desired?; (4) How is the maximum sensitivity or specificity achieved?; (5) how is the predictive value maximized? An essential understanding of these factors is required to enable the skilled artisan to accurately use and interpret any given diagnostic test. Since the specification lacks any teaching of how the diagnostic tests were performed, or any information regarding the patients from which the samples were taken, and whether any considerations were given to any of the characteristics state above, it would require undue experimentation for one skilled in the art to make and use the invention as claimed.

The specification lacks proper guidance to enable one skill in the art to determine the incidence of disease as related to the presence or absence of a biopolymer that correspond to the maker having SEQ ID NO. 1. The specification further lack proper guidance to enable one skilled in the art to distinguish between any and all disease states as claimed.

Because of the lack of description in the specification for the claimed method, it cannot be conclusively determined from the data presented in Figure 1 nor the declaration that anyone or everyone who has this polypeptide marker suffers from any diseases, specifically MI and

Art Unit: 1641

renal failure. Patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. See *Brenner v. Manson*, 383 U.S. 519, 536, 148 USPQ 689, 696 (1966) (stating, in context of the utility requirement, that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion.") Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable members of the public to understand and carry out the invention. *Genentech Inc. v. Novo Nordisk A/S* (CAFC) 42 USPQ2d 1001. That requirement has not been met in this specification with respect to a method for diagnosing MI and renal failure by detecting a biopolymer marker in a patient sample and comparing the detected biopolymer to a biopolymer marker having SEQ ID. NO. 1.

Therefore, it is maintained that one of ordinary skill in the art could not make and use the invention as claimed without undue experimentation.

### *Response to Arguments*

12. Applicant's arguments filed June 13, 2003 and October 3, 2003 have been fully considered but they are not persuasive in view of the new ground(s) of rejection.

With respect to the declaration purposely showing a side-by-side comparison of normal sera versus sera from a patients having MI, and that this profile clearly evidences the absence of the 1350 dalton marker in normal sera and thus establishes the specificity of the 1350 dalton peptide as a marker diagnostic for MI.

Art Unit: 1641


It has been fully considered but is not deemed to be persuasive. A showing of one patient sample and one negative control does not lead to a generalization that the presence of such marker is diagnostic for MI, i.e. it does not necessarily show the specificity of the marker to a specific disease. Specifically, there is no consideration of the specificity, or percentage of patients without the disease who will display a negative result; nor is there a consideration of the sensitivity of the assay, the true-positive test rate, the false-negative test rate, the predictive value, or the probability that the test result is correctly indicating the presence or absence of the disease, etc. Furthermore, the declaration does not show how such a marker identifies a patient as either suffering from MI or renal failure as claimed.

### *Conclusion*

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao-Thuy L. Nguyen whose telephone number is (571) 272-0824. The examiner can normally be reached on Tuesday and Thursday from 9:00 - 4:30 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (703) 305-3399. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
BAO-THUY L. NGUYEN  
PRIMARY EXAMINER  
5/3/04